Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy

Gelijkaardige items

• Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data
  door: Fassoni, Artur C., et al.
  Gepubliceerd in: (2018)
• Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment
  door: Jaeger, Bernadette Anna Sophia, et al.
  Gepubliceerd in: (2012)
• Quantitative prediction of long-term molecular response in TKI-treated CML – Lessons from an imatinib versus dasatinib comparison
  door: Glauche, Ingmar, et al.
  Gepubliceerd in: (2018)
• Impact of the type of the BCR-ABL fusion transcript on the molecular response in pediatric patients with chronic myeloid leukemia
  door: Suttorp, Meinolf, et al.
  Gepubliceerd in: (2010)
• Impact of Long-Term Exposure to the Tyrosine Kinase Inhibitor Imatinib on the Skeleton of Growing Rats
  door: Tauer, Josephine T., et al.
  Gepubliceerd in: (2015)